Patent Application
20230287495
The instant application contains a Sequence Listing which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 5, 2020, is named P2020-0958_amended_Sequence_listing_PN41046_SCBG01US.txt, and is 5,698 bytes in size.
The invention relates to the field of biological detection, and more specifically to a reagent and method for detecting RCL by fluorescence quantitative real-time PCR.
The biggest security risk in gene/cell therapy using lentivirus as a vector is the production of Replication Competent Lentivirus (RCL). Although the existing lentivirus production system has greatly reduced the possibility of RCL production, there is still a certain risk of RCL production, and an appropriate detection program is still needed to detect RCL. According to the recommendations in the FDA RCR Guidance issued by US FDA in 2006 and the FDA Recommendations issued in 2010, it is necessary to monitor RCL conditions for products and patient samples of gene/cell therapy using lentivirus as a vector. The detection methods recommended by FDA Recommendations include: 1) detection of RCL-related proteins; 2) detection of RCL-specific DNA sequences in samples using Quantitative real-time PCR (qPCR) method. The standard cell co-cultivation method for detecting RCL has a long cycle, and it takes about 6 weeks or longer to obtain experimental results.
TaqMan probe method is a highly specific quantitative PCR technology. The core is to use the 3′→5′ exonuclease activity of Taq enzyme to cut off the probe to generate a fluorescent signal. Since the probe and the template are specifically bound, the intensity of the fluorescence signal represents the quantity of the templates. The FDA now allows the use of TaqMan probes, i.e. hydrolysis probes, qPCR method to quickly detect the RCL conditions in products. However, the current primers and probes for detecting RCL have the problems of low amplification efficiency and poor specificity. There is an urgent need in this field to develop new reagents and methods for detecting RCL by fluorescence quantitative real-time PCR.
The purpose of the present invention is to provide a reagent and method for detecting RCL by fluorescence quantitative real-time PCR.
More specifically, the purpose of the present invention is to provide a reagent and method for detecting the copy number of specific VSV-G gene of replication-competent lentivirus (RCL) by TaqMan fluorescence quantitative real-time PCR.
In a first aspect of the present invention, it provides a reagent combination comprising:
In another preferred embodiment, the reagent combination further comprises:
In another preferred embodiment, the probe is coupled with or has a detectable label.
In another preferred embodiment, the detectable label is selected from the group consisting of a chromophore, a chemiluminescent group, a fluorophore, an isotope and an enzyme.
In another preferred embodiment, the reagent combination is used for detecting Replication Competent Lentivirus (RCL).
In another preferred embodiment, the lentivirus uses Vesicular stomatitis virus-G protein (VSV-G) as the envelope protein.
In another preferred embodiment, the amplification efficiency of the reagent combination for detecting RCL is ≥90%, preferably ≥92%, and more preferably ≥95%.
In a second aspect of the present invention, it provides a PCR amplification system comprising: a buffer system for amplification and the primer combination of the first aspect of the present invention located in the system.
In a third aspect of the present invention, it provides a detection reagent comprising the primer combination of the first aspect of the present invention.
In another preferred embodiment, the detection reagent is used for detecting RCL.
In a fourth aspect of the present invention, it provides a detection kit comprising one or more containers, and the primer combination of the first aspect of the present invention located in the containers.
In another preferred embodiment, the detection kit is used for detecting RCL.
In another preferred embodiment, the first primer pair and the first probe are located in the same or different containers.
In another preferred embodiment, the second primer pair and the second probe are located in the same or different containers.
In another preferred embodiment, the third primer pair and the third probe are located in the same or different containers.
In another preferred embodiment, the third primer pair and the third probe are located in the same container as the first primer pair and the first probe.
In another preferred embodiment, the third primer pair and the third probe are located in the same container as the second primer pair and the second probe.
In another preferred embodiment, the kit further comprises reagents for amplification.
In another preferred embodiment, the reagents for amplification comprise a buffer, dNTP, and an amplification enzyme.
In another preferred embodiment, the kit further comprises an instruction manual.
In a fifth aspect of the present invention, it provides a detection method for detecting RCL, which comprises:
In another preferred embodiment, the envelope protein of the RCL is Vesicular stomatitis virus-G protein (VSV-G).
In another preferred embodiment, the method is a TaqMan probe method.
In another preferred embodiment, in step (b), in a same amplification system, the first primer pair for specific amplification of VSV-G gene and the first probe are together used with the third primer pair for specific amplification of reference gene and the third probe, to perform fluorescence quantitative real-time PCR on the DNA sample to be tested.
In another preferred embodiment, in step (b), in a same amplification system, the second primer pair for specific amplification of VSV-G gene and the second probe are together used with the third primer pair for specific amplification of reference gene and the third probe, to perform fluorescence quantitative real-time PCR on the DNA sample to be tested.
In another preferred embodiment, in step (b), a positive control and a negative control are tested.
In another preferred embodiment, the method is a non-diagnostic and non-therapeutic method.
In another preferred embodiment, the method is an in vitro method.
In another preferred embodiment, in step (a), the DNA sample to be tested is extracted from a sample selected from the group consisting of: (i) a replication competent lentivirus, (ii) a biological product using lentivirus as a vector, and (iii) blood, bone marrow fluid, tissues and organs of human or an animal (such as a rodent, primate).
In another preferred embodiment, the human or animal described in (iii) has been administered with a biological product using lentivirus as a vector.
In another preferred embodiment, the lentivirus is a replication competent lentivirus.
In another preferred embodiment, the biological product using lentivirus as a vector is selected from the group consisting of:
Master Cell Bank (MCB), Working Cell Bank (WCB), End of Production (EOP) Cells, Vector-Containing Supernatant, Virus Infected Cells (Ex Vivo Transduced Cells), and a combination thereof.
It is to be understood that the various technical features of the present invention mentioned above and the various technical features specifically described hereinafter (as in the Examples) may be combined with each other within the scope of the present invention to constitute a new or preferred technical solution, which needs not be described one by one, due to space limitations.
Through extensive and intensive research, the inventors have unexpectedly discovered for the first time a primer and probe combination for detecting RCL by fluorescence quantitative real-time PCR, and a method for performing detection using the primer and probe. The present invention also provides a reagent kit comprising the primer and probe. Experiments have shown that using the primer and probe combination of the present invention to detect RCL has high amplification efficiency and good specificity, and is suitable for clinical and laboratory detection. The present invention has been completed on the basis of this.
Specifically, the primer and probe combination of the present invention can be used for detection of RCL which may be produced during a production process and for RCL monitoring of clinical patient peripheral blood samples. The present invention also established and verified a method for detecting VSV-G sequence of a sample with the primer and probe combination of the present invention using the Taqman probe method, using human genomic DNA as background.
Vesicular stomatitis virus-fusion promoting envelope G protein (VSV-G) is a glycosylated membrane protein, which plays a decisive role in the two initial steps of virus entry into host cells: the attachment of the virus to the surface of the host cell and the pH-dependent endosomal membrane fusion induced by the virus.
VSV-G is an envelope protein with a wide host range, which can infect most human cells, and cells from species far away from humans such as zebrafish and drosophila. It is currently widely used in lentiviral vectors, and it can expand the infective lineage of lentiviral vectors. VSV-G plays an important role in gene and cell therapy.
TaqMan qPCR
TaqMan probe method is a highly specific quantitative PCR technology. The core is to use the 3′→5′ exonuclease activity of Taq enzyme to cut off the probe to generate a fluorescent signal. Since the probe and the template are specifically bound, the intensity of the fluorescence signal represents the quantity of the templates.
The quantitative PCR reaction system of the TaqMan probe method comprises a pair of PCR primers and a probe. The probe only specifically binds to the template, and its binding site is between the two primers. The 5′ end of the probe is labeled with a reporter group (Reporter, R) such as FAM, VIC, etc. The 3′ end is labeled with a fluorescence quencher group (Quencher, Q), such as TAMRA, etc. When the probe is complete, the fluorescent energy emitted by the reporter group is absorbed by the quencher group, and an instrument cannot detect the signal. As the PCR progresses, Taq enzyme encounters the probe bound to the template during the chain extension process, and its 3′→5′ exonuclease activity will cut off the probe. Therefore the reporter group will be taken far away from the quencher group, and its energy will not be absorbed. That is, a fluorescent signal will be generated. Therefore, after each PCR cycle, the fluorescent signal also has a synchronous exponential growth process like the target fragment. The intensity of the signal represents the copy number of the template DNA.
As used herein, the term “probe” refers to a gene probe, that is, a nucleic acid probe, which is a nucleic acid sequence (DNA or RNA) complementary to the target gene with a detection label and a known sequence. The gene probe combines with the target gene through molecular hybridization to generate a hybridization signal, which can reveal the target gene from the vastest genome.
Reagent Combination
The present invention relates to a reagent combination for detecting RCL, comprising:
The reagent combination of the present invention is used in the Taqman probe method to detect RCL, and has high amplification efficiency and good specificity.
Detection Method and Detection Kit
The present invention relates to a detection method for detecting RCL, wherein the method comprises: using the reagent combination of the first aspect of the present invention to perform fluorescence quantitative real-time PCR on a DNA sample to be tested; and calculating the Cq value and VSV-G gene copy number of the DNA sample to be tested to determine whether the sample contains RCL.
The method of the present invention can detect a sample selected from the group consisting of: (i) a replication competent lentivirus, (ii) a biological product using lentivirus as a vector, and (iii) blood, bone marrow fluid, tissues and organs of human or an animal (such as a rodent, primate).
The Main Advantages of the Present Invention Include:
The present invention will be further illustrated below with reference to the specific examples. It is to be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the invention. For the experimental methods in the following examples the specific conditions of which are not specifically indicated, they are performed under routine conditions, e.g., those described by Sambrook et al., in Molecule Clone: A Laboratory Manual, New York: Cold Spring Harbor Laboratory Press, 1989, or as instructed by the manufacturers, unless otherwise specified. Unless indicated otherwise, parts and percentage are weight parts and weight percentage.
General Materials
1. Main Reagents
2. Primer and Probe Information
VSV-G1 to VSV-G4 primers were synthesized by GenScript, and the probes were synthesized by Invitech (VSV-G2 was not included).
VSV-G5 and VSV-G6 primers and probes were synthesized by GenScript.
VSV-G7 to VSV-G10 primers and robes were synthesized b Invitech.
VSV-G1 primers and probes were designed with reference to Escarpe P I Zayek N, Chin P, Borellini F, Zufferey R, Veres G, and Kiermer V, Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations, Mol Ther. 2003 August; 8(2):332-41.
RPP30 and TERT primers were synthesized by GenScript. RPP30 and TERT probes were synthesized b Invitech.
4. C8166 Cell Line
The C8166 cell line is a human leukemia cell, which is liable to lentivirus infection and entry. It was used as a susceptible host of lentivirus in the RCL detection by cell co-culture method, which is conducive to the replication and amplification of low-level RCL.
5. Standard
The standard was used for preparing standard curves to establish a quantitative relationship between the quantification cycle (Cq) and the copy number. In the present program, the CBMG-PRM1 plasmid containing the VSV-G sequence was doubly diluted and 100 ng of human genomic DNA was added as a background, then the mixture was used as a standard.
6. Quality Control-Negative Control (NC)
Negative control standards include: No template control (NTC), which only lacks template in the qPCR reaction system for detecting the presence of dimer and reagent contamination; background negative control (BNC), using C8166 genomic DNA (gDNA) or human non transduced T cell (hNT) gDNA as the template in the qPCR reaction system for detecting the influence of gDNA on qPCR amplification, which can also be used for monitoring the contamination of reagents and sample loading process.
7. Quality Control-Positive Control (PC) The quality control-positive control is the background gDNA of the same concentration (set as 100 ng in the present experiment) containing different copy numbers of CBMG-PRM1 plasmids. Quality control-positive control is used for evaluating the performance of the experiment.
General Methods
Screening of VSV-G Primers/Probes by TaqMan qPCR Method Screening criteria: 1) Correlation coefficient (R2) ≥0.99; 2) Amplification efficiency (Efficiency): 90%-110%; 3) No amplification of NTC and BNC.
qPCR Detection Experiment Process
The following quality control-positive controls are required in this method validation:
104
106
The above quality control-positive controls were diluted in one batch and then sub packaged in 15 μl/tube/test and cryopreserved at −80° C. to avoid repeated freezing and thawing.
The following reagents were taken from −80° C. refrigerator and placed at 4° C. after thawing: 1010 copies/μl CBMG-PRM1 plasmid stock solution, 1010 copies pUC57-TERT plasmid stock solution, 1010 copies/μl pUC57-RPP30 plasmid stock solution, T cell gDNA (C8166 gDNA or hNTgDNA), quality control-positive control;
109
108
107
106
105
104
103
102
1010
109
108
107
106
105
104
103
102
Note: When single CBMG-PRM1 plasmid is used as a standard, and no gDNA is used as a background control, step (1) is sufficient.
106
105
104
103
102
4.2 Doubling Dilution of Double-Plasmid Standard (Containing VSV-G Plasmids and Reference Gene Plasmids, No Background gDNA)
According to the method shown in the following table, the standards were diluted in 1.5 ml centrifuge tubes with diluent in turn and centrifuged in a micro centrifuge; the operation was taken place on ice and the products were placed at 4° C. for use to obtain double-plasmid standard solutions of different concentrations/copy numbers:
109
108
107
106
105
104
103
102
1010
109
108
107
106
105
104
103
102
1010
109
108
107
106
105
104
103
102
5.1 Preparation of CBMG-PRM1 Plasmid+100 ng gDNA Reaction System (Including the Standard and Quality Control-Positive Control) (Mix-VSV-G)
The above solutions were added to 1.5 ml centrifuge tubes, operated on ice, mixed upside down, centrifuged in a micro centrifuge, and placed at 4° C. for use.
The above solutions were added to 1.5 ml centrifuge tubes, operated on ice, mixed upside down, centrifuged in a micro centrifuge, and placed at 4° C. for use.
The above solutions were added to 1.5 ml centrifuge tubes, operated on ice, mixed upside down, centrifuged in a micro centrifuge, and placed at 4° C. for use.
The above solutions were added to 1.5 ml centrifuge tubes, operated on ice, mixed upside down, centrifuged in a micro centrifuge, and placed at 4° C. for use.
5.5 Preparation of Double-Plasmid Standard Duplex qPCR Reaction System
The above solutions were added to 1.5 ml centrifuge tubes, operated on ice, mixed upside down, centrifuged in a micro centrifuge, and placed at 4° C. for use.
5.6 Preparation of Single Plasmid Standard Duplex qPCR Reaction System
The above solutions were added to 1.5 ml centrifuge tubes, operated on ice, mixed upside down, centrifuged in a micro centrifuge, and placed at 4° C. for use.
6. qPCR Detection
6.1 Single-Plex qPCR Detection
Standard Conditions:
Annealing/Extension: 60 sec at 60° C.
6.2 Detection of Double-Plasmid Standard Duplex qPCR
Standard Conditions:
If any one of the above 3 points does not meet the requirements, the experiment needs to be repeated.
According to the standard curve, the Cq value of each sample and the VSV-G gene copy number of 100 ng genome was outputted by software automatically;
In order to facilitate the determination of the positive and negative results of RCL, the copy number of LOD+100 ng C8166 gDNA was used as the quality control-positive control (PC) in the experiment. The average Cq value of each experiment was used as the positive threshold.
Screening of Primer/Probe Pairs for the Reference Gene
Doubly diluted 293T gDNA was used for making standard curve, to test two primer/probe pairs RPP30 and TERT.
The results are shown in Table 1. The amplification efficiency of RPP30 was 99.24%, and the amplification efficiency of TERT was 83.22%.
pUC57-RPP30 plasmid doubling dilution was used for making a standard curve once again to test the effectiveness of RPP30 primer/probe. The results showed that the amplification efficiency of RPP30 primer/probe was 93.77%, and R2 was 0.995. Follow-up experiments were conducted with primer/probe pairs of RPP30.
Screening of Probe/Primer Pairs for VSV-G Gene Detection
Doubly diluted 293T gDNA was used to make standard curve, to test VSV-G1, VSV-G3, VSV-G4, VSV-G5, VSV-G6, VSV-G7, VSV-G8, VSV-G9 primer/probe pairs.
The results are shown in Table 2. From the perspective of amplification efficiency, the amplification efficiencies of VSV-G4, VSV-G6, VSV-G8, and VSV-G9 are between 90% and 110%. However, the background of VSV-G6 was relatively high. When only 293T gDNA was used as the background template, the Cq value was 38.6. While the sensitivity of VSV-G4 was relatively low. When the VSV-G template was 10 copies, the Cq value was 39.2, when 106 copies, the Cq value is 21.8. The sensitivity of VSV-G1 was also relatively low. The Cq value was 38.3 when the VSV-G template was 10 copies.
Table 2 the concentration of each VSV-G primer/probe pair and the result parameter informations with 293T gDNA as background control
CAR-NCgDNA and C8166 gDNA were used as background templates respectively. The amplification efficiencies, R2 and background conditions of VSV-G6, VSV-G8, VSV-G9 primers/probes were detected again.
The results with CAR-NCgDNA as a background control are shown in Table 3. The results with C8166gDNA as a background are shown in Table 4. The results showed that VSV-G6 primer/probe and 293T gDNA had non-specific binding and amplification. VSV-G8 and VSV-G9 primers/probes had good specificity under three genomic backgrounds: 293T, C8166, and NC (non-transduced T cells), and the amplification efficiencies were also 90%˜110%. In the subsequent double probes/primers test, VSV-G8 and VSV-G9 primers/probes were used for testing.
Detection of the Amplification Efficiency of VSV-G Primer/Probe and Reference Gene Primer/Probe in the Same Reaction Well by Double-Plasmid Method
The VSV-G plasmids (CBMG-PRM1) and the reference gene plasmids (pUC57-RPP30) were doubly diluted by 10 times and placed in a same well as a template to establish a standard curve. Duplex PCR was performed to detect the interference of the two probe/primer pairs. In this example, the combination of VSV-G8 and internal reference RPP30 and the combination of VSV-G9 and internal reference RPP30 were tested.
The results are shown in Table 5. In the duplex PCR reaction of the VSV-G8/RPP30 primer probe combination, neither the amplification of VSV-G8 nor the amplification of RPP30 was significantly affected. In the duplex PCR reaction of the VSV-G9/RPP30 primer probe combination, neither the amplification of VSV-G9 nor the amplification of RPP30 was significantly affected.
The result parameters of the two probe/primer pairs detected by duplex PCR are as follows:
Detection of Double Primer/Probe PCR Reaction Under Single Plasmid+High-Quality Background
Single plasmid was used for making standard curve. VSV-G gene copy number detection was performed by duplex PCR detection under high-quality background (C8166 and NT, 1000 ng). The amplification efficiencies of the VSV-G primer/probe and reference gene primer/probe and the effect of high-quality background on duplex PCRVSV-G were tested in the same reaction well.
The results are shown in Table 6. The amplification efficiencies of VSV-G8 and VSV-G9 were relatively high under the background of high-quality genome, and the amplification efficiency of VSV-G9 is higher.
All literatures mentioned in the present application are incorporated herein by reference, as though each one is individually incorporated by reference. In addition, it should also be understood that, after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications, equivalents of which falls in the scope of claims as defined in the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201810114113.2 | Feb 2018 | CN | national |
This is a U.S. national phase application under 35 U.S.C. § 371 of Patent Cooperation Treaty Application No. PCT/CN2019/072576, filed Jan. 21, 2019, which claims priority from Chinese Patent Application Serial No. 201810114113.2, filed on Feb. 5, 2018, and which incorporates by reference those PCT and Chinese applications in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16967659 | Aug 2020 | US |
| Child | 18321141 | US |
